Help to Grow programme: CASE STUDY

EMER GILLESPIE Owner and Chief Executive Officer Spark & Bell

❛❛ The course has helped me realise that I am not alone, that the issues and problems I face leading an SME are similar to those faced by others. It has made me appreciate that I know more than I thought, but there is still more to learn as I want to be the most effective leader I can be.

I particularly enjoyed the finance module; this helped me get my head around an area that I was not as familiar with. The face-to-face workshop has made me much more confident around figures and the financial planning tools. I cannot wait to get stuck in.

I’ve already told someone I know they really must sign up as they would really benefit from the course. What I would say is that Help to Grow Management is a great course to give

Special Offer

you a helicopter view of all that is involved in running a small business, it helps identify areas to work on and it’s a great opportunity to network with other like-minded people.

Here at Spark & Bell, we are passionate about lighting. Our handmade products ensure that you have a unique lighting experience that reflects you and your needs. ❜❜

GILLESPIE OWNER AND CHIEF EXECUTIVE OFFICER Spark & Bell

90% of the programme cost is covered by the Government therefore a total cost of £750. The good news is that for Dynamic readers there are a number of FREE places for women on the Gatwick programme when you quote PLATINUM100 when signing up. MORE INFORMATION

WWW.BRIGHTON.AC.UK/HELP-TO-GROW

GAME-CHANGING BLOOD TEST

As we know, early detection of cancer is crucial. The University of Oxford and the NHS have been trialing a new blood test with very positive outcomes. The Galleri test appears capable of detecting 50 types of early-stage cancers, often before symptoms show, by flagging up fragments of tumour DNA, even pinpointing where in the body they originated.

Trials involved 5,500 people with suspected cancer and the blood test correctly identified two-thirds of positive cases. In the vast majority of diagnoses – 85% – it also revealed the site of the cancer.